BEDFORD, Mass., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus") (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced the appointment of Julie Eastland, an experienced biotechnology and financial executive, to Lantheus' Board of Directors ("Board"), effective as of September 3, 2024. As an independent director, Ms. Eastland will serve as a member of the Boa ...

Financial Data and Key Metrics Changes - Consolidated net revenue for Q2 2024 was $394.1 million, an increase of 22.5% year-over-year [17] - Adjusted net income for Q2 was $126.8 million, reflecting a 15.7% increase [20] - Fully diluted earnings per share for Q2 were $1.80, up 16.4% [20] Business Line Data and Key Metrics Changes - PYLARIFY generated net sales of over $273 million, up nearly 30% from the prior year [8] - DEFINITY reported net sales of approximately $78 million, an increase of almost 11% year-over-year [13] - TechneLite revenue was $28.2 million, up 30.5% due to opportunistic sales [17] Market Data and Key Metrics Changes - The addressable market for PYLARIFY is expected to grow from over $2 billion in 2024 to north of $3 billion by 2029 [12] - PSMA PET scans currently represent approximately 30% of prostate cancer scans, indicating significant growth potential [12] Company Strategy and Development Direction - The company aims to enhance its leadership by maximizing the value of its existing portfolio and expanding its innovative pipeline through focused business development and M&A [4] - Recent acquisitions include NAV-4694 and RM2, which are expected to address high unmet medical needs in Alzheimer's and prostate cancer diagnostics [5][6] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in sustaining broad patient access to PYLARIFY and highlighted the importance of strategic partnerships [11] - The company anticipates continued growth in PYLARIFY sales, driven primarily by volume, despite potential pricing pressures [42] Other Important Information - The company has a strong liquidity position with cash and cash equivalents totaling $757 million [21] - R&D expenses increased significantly to support the advancement of MK-6240 and other pipeline assets [19] Q&A Session Summary Question: Thoughts on PYLARIFY and CMS recommendation - Management acknowledged the positive CMS proposal for separate payment for PYLARIFY and emphasized ongoing engagement with stakeholders to maximize patient access [29][30] Question: R&D step-up and earnings guidance - The increase in R&D spending is primarily due to investments in MK-6240 and other business development costs, with expectations for continued investment aligned with commercial opportunities [31][32] Question: PYLARIFY revenue growth trends - Management expects PYLARIFY to grow in the mid-20% range, with Q4 anticipated to be stronger than Q3 due to seasonal trends [34][59] Question: Size of Alzheimer's opportunity - The total addressable market for Alzheimer's diagnostics is significant, with management expressing optimism about the potential for growth in this area [38][39] Question: Competitive landscape for PYLARIFY - Management remains confident in PYLARIFY's market leadership, citing its clinical and commercial advantages despite the presence of competitors [46][51]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 For the transition period from to FORM 10-Q Commission File Number 001-36569 (Mark One) LANTHEUS HOLDINGS, INC. (Exact name of registrant as specified in its charter) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | Delaware | 35-2318913 | | - ...

Exhibit 99.1 Second Quarter 2024 • Completed three strategic transactions to expand innovative pipeline • The Company maintains full year 2024 revenue guidance and updates fully diluted earnings per share guidance driven by strategic transactions "We delivered another strong quarter as we continued to maximize the value of our commercial portfolio," said Brian Markison, Chief Executive Officer of Lantheus. "With the strength of our balance sheet and radiopharmaceutical expertise, we also announced three str ...

Financial Performance - Worldwide revenue reached $394.1 million, marking a 22.5% increase from the second quarter of 2023 [28][41] - GAAP net income was $62.1 million, a decrease of 34.1% compared to $94.1 million in the prior year [28][41] - GAAP fully diluted earnings per share (EPS) decreased to $0.88 from $1.33 in the same period last year, reflecting a 33.7% decline [28][41] - Adjusted net income (non-GAAP) increased by 15.7% to $126.8 million, while adjusted fully diluted EPS rose 16.4% to $1.80 [28][41] Strategic Transactions - The company completed three strategic transactions aimed at expanding its innovative pipeline [27][13] - Acquired NAV-4694, which is in Phase 3 clinical trials for Alzheimer's disease, enhancing its position in the market [16] - Acquired global rights to RM2, targeting the gastrin-releasing peptide receptor, which strengthens its presence in prostate cancer [16] Product Performance - Sales of PYLARIFY reached $273.3 million, a 29.8% increase from $210.5 million in the prior year, driven by increased utilization in the PSMA PET imaging market [41][36] - DEFINITY sales were $78.1 million, up 10.7% from $70.5 million in the previous year [41][36] Guidance and Future Outlook - The company maintains its full-year 2024 revenue guidance of $1.50 billion to $1.52 billion, while adjusting its fully diluted EPS guidance to $6.60 - $6.70 [17] - The final rule from the Centers for Medicare & Medicaid Services (CMS) regarding payment for specialized diagnostic radiopharmaceuticals is expected to be issued in early November 2024 [4] Balance Sheet Highlights - Cash and cash equivalents increased to $757.0 million from $713.7 million at the end of 2023 [29][12] - Total assets grew to $1.94 billion, up from $1.65 billion at the end of 2023 [12][39]

Contacts: Mark Kinarney Vice President, Investor Relations 978-671-8842 ir@lantheus.com Melissa Downs Senior Director, External Communications 646-975-2533 media@lantheus.com BEDFORD, Mass., July 17, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the "Company") (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Wednesday, July 31, 2024, to discuss its financial and operating results for the second quarter of 2024. To access the conference call or webcast, pa ...

To access the conference call or webcast, participants should register online at https://investor.lantheus.com/news-events/calendar-of-events. To avoid delays, we encourage participants to register fifteen minutes ahead of the scheduled start time. Lantheus is the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes. Headquartered in Massachusetts with offices in Canada and Sweden, Lantheus has ...

Core Insights - Lantheus Holdings, Inc. supports the CMS's proposed OPPS rule for 2025, which aims to improve payment for specialized diagnostic radiopharmaceuticals, enhancing patient access for Medicare beneficiaries [1][6] Company Overview - Lantheus is a leading company in the radiopharmaceutical sector, focused on enabling clinicians to diagnose and treat diseases effectively, thereby improving patient outcomes [15] - The company has been providing radiopharmaceutical solutions for over 65 years and operates in Massachusetts, Canada, and Sweden [15] Product Information - PYLARIFY (piflufolastat F 18) is a PSMA-targeted PET imaging agent that allows visualization of metastatic prostate cancer, demonstrating superior diagnostic performance [2][9] - PYLARIFY is the most ordered PSMA PET imaging agent in the U.S., with over 350,000 scans conducted across 48 states [2] Regulatory Developments - The proposed CMS rule suggests that diagnostic radiopharmaceuticals with a per day cost exceeding $630 will be paid separately, which is a shift from the current packaging policy [6] - The proposed rule will undergo a 60-day comment period ending on September 9, 2024, with the final rule expected in early November 2024, taking effect on January 1, 2025 [6]

BEDFORD, Mass., July 10, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus") (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, announced that it welcomes the Centers for Medicare & Medicaid Services' (CMS') Proposed Medicare Hospital Outpatient Prospective Payment System (OPPS) Rule for calendar year 2025 for improved payment for specialized diagnostic radiopharmaceuticals to suppor ...

Investors are cheering a proposed rule that could boost Lantheus' revenue. In the past, CMS has bundled the costs of diagnostic radiopharmaceuticals in with the payment for related nuclear medicine tests. The agency said that in some cases, this payment doesn't fully cover the cost of the associated diagnostic radiopharmaceuticals. CMS is proposing to pay for diagnostic radiopharmaceuticals with a cost greater than $630 per day separately from the nuclear medicine tests. Roughly 70% of Lantheus' total reven ...